Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT06202066
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 11
- Registration Number
- NCT05677633
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
- Conditions
- Anatomic Stage IB Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 33
- Registration Number
- NCT05455658
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT05242965
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 42
- Registration Number
- NCT04902703
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Sargramostim Use in COVID-19 to Recover Patient Health
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT04707664
- Locations
- 🇺🇸
Dorrington Medical Associates, Houston, Texas, United States
🇺🇸Synergy Healthcare, Bradenton, Florida, United States
🇺🇸Hometown Urgent Care and Research, Columbus, Ohio, United States
A Phase II/III Study of Sargramostim
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Nobelpharma
- Target Recruit Count
- 70
- Registration Number
- NCT04642950
- Locations
- 🇯🇵
Mishuku Hospital, Meguro-ku, Tokyo, Japan
🇯🇵Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan
🇯🇵Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan
Study of Sargramostim in Patients With COVID-19
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04411680
- Locations
- 🇺🇸
Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT04400929
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.